One More Stock Investors Ought To Pay Attention To Is Akero Therapeutics Inc (NASDAQ: AKRO)

During the last session, Akero Therapeutics Inc (NASDAQ:AKRO)’s traded shares were 0.46 million, with the beta value of the company hitting -0.29. At the end of the trading day, the stock’s price was $19.92, reflecting an intraday loss of -3.91% or -$0.81. The 52-week high for the AKRO share is $58.38, that puts it down -193.07 from that peak though still a striking 43.52% gain since the share price plummeted to a 52-week low of $11.25. The company’s market capitalization is $1.38B, and the average trade volume was 1.25 million shares over the past three months.

Akero Therapeutics Inc (NASDAQ:AKRO) trade information

Akero Therapeutics Inc (AKRO) registered a -3.91% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -3.91% in intraday trading to $19.92, hitting a weekly high. The stock’s 5-day price performance is 1.37%, and it has moved by -2.88% in 30 days. Based on these gigs, the overall price performance for the year is -56.97%.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Akero Therapeutics Inc (AKRO) estimates and forecasts

Statistics show that Akero Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Akero Therapeutics Inc (AKRO) shares have gone up 35.97% during the last six months, with a year-to-date growth rate less than the industry average at -32.53% against 14.10.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 1.03%. While earnings are projected to return -33.39% in 2024, the next five years will return -14.60% per annum.

AKRO Dividends

Akero Therapeutics Inc is due to release its next quarterly earnings in June. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.